There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – ...

AN2 Therapeutics, Inc. ( (ANTX)) has shared an announcement. AN2 Therapeutics has promoted its Chief Legal Counsel, Joshua Eizen, to the roles of Chief Legal Officer and Chief Operating Officer, ...

The measures taken as a result of losing the deal include cutting staff, which would occur with immediate effect.

If ultimately fully funded, the MPC2SC Program will start by identifying 10 students at the community college during their ...

The company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared ...

Coya Therapeutics said that the q2wks group, representing the higher total dose cohort, did not exhibit benefits in exploratory endpoints. Coya Therapeutics will likely advance LD IL-2 q4wks.

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced Enchant™, a multi-modal transformer model ...

The global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, projected to expand at a CAGR of 6.3% from 2023 ...